BRII-179 showed 32% HBsAg loss durability at 24 weeks post-treatment in the Phase 2b ENRICH study, with consistent results ...

Eton's ET-700 shows better tolerability than GALZIN but reduced efficacy in Wilson disease pilot study with 12 patients per ...

ATG-201 Phase I trial opens in China for B cell autoimmune diseases, testing a CD19×CD3 bispecific with masking technology to ...

ICON's AI-directed video engine cuts clinical trial video production time by 90%, streamlining site selection and training ...

Citius Oncology presents LYMPHIR quality-of-life data from pivotal Study 302 at EORTC meeting, supporting formulary ...

Ivonescimab perioperative NSCLC study shows 50.7% pathological complete response rate, outpacing current standard-of-care ...

Clinical research sites report trial complexity as their top operational problem, with 41% naming it their biggest challenge ...

Hengrui Pharma presents 64 studies at ESMO 2026, a record for the Chinese oncology company showcasing 14 approved innovative ...

Regulatory gaps and organizational challenges slow AI adoption in clinical trials despite proven 90% reductions in data ...

PROSpect's phase 3 RCT enrolled 424 children with PARDS and found neither prone positioning nor HFOV improves ventilator-free ...

Zhimeng Biopharma completes enrollment of CB03-154 Phase 2/3 ALS trial with 255 patients across China, targeting Q3 2027 ...

PharPoint Research joins Medrio's Early Adopter Program to shape clinical trial management system design before product ...